Short description
Remegen is a biotech company focused on discovering and developing a new generation of targeted therapies for the treatments of cancer.
Description
RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.
Last funding
Blurry Noaccess
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Yantai, Liaoning, China, Asia
Founded on
January 1, 2008
Exited on
April 1, 2022
Went public on
April 1, 2022
Stock symbol
688331
Non-profit?
No
Acquired?
No
Employees count
1001-5000
Revenue range
$7890 - 12340
Sign in for full access
Investors
Absolutely Noaccess, Nopepepe, Uh Ohhhh, No Way, Absolutely Noaccess, No Way, Noaccess, Uh Ohhhh, Noaccess, Blurry Noaccess, Cannot Access, Noaccess, Nopepepe, Nopepepe, Noway Youcantaccess, Uh Ohhhh, No Way, No Way
Sign in for full access
Founders
Jianmin Fang, Wang Weidong
Funding rounds count
1
Portfolio organisations count
Noaccessforu, Uh Ohhhh
Sign in for full access
Exits count
Nopepepe, Cannot Access
Sign in for full access
IPO exits count
1